HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Lilly, Gilead lead pharma’s M&A boom

Deal volume in 2026 is far outpacing last year, and is being driven by cancer and autoimmune disease drugs.

By PharmaVoice · May 7, 2026 · via PharmaVoice
Lilly, Gilead lead pharma’s M&A boom

Image: PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice →

Tags
dealsformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
BMS Bets on China’s Speed in $15B Hengrui R&D Pact
DealsBriefing
BMS Bets on China’s Speed in $15B Hengrui R&D Pact
Bristol Myers Squibb will pay $600M upfront in a $15.2B collaboration with Hengrui, aiming to leverage China’s…
May 12, 2026
GSK cuts deal with Sino to broaden reach of hepatitis B drug
DealsBioPharma Dive ↗
GSK cuts deal with Sino to broaden reach of hepatitis B drug
The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and c…
May 11, 2026
Blackstone invests $250M in Anagram to reduce burden of cystic fibrosis complication
DealsFierceBiotech ↗
Blackstone invests $250M in Anagram to reduce burden of cystic fibrosis complication
For people living with exocrine pancreatic insufficiency due to cystic fibrosis, the only treatment option is …
May 10, 2026